Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.
White Paper Declaration
